News | July 06, 2022
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Formula attenuates 99% of 365 coronaviruses in computer models
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The expansion makes Exothera one of the largest viral vector facilities in Europe
Subscribe To Our Newsletter & Stay Updated
